Tandem Diabetes Care

OverviewSuggest Edit

Tandem Diabetes Care is a medical device company that engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is primarily focused on manufacturing, sales, and support of its flagship pump platform, t:slim X2 Insulin Delivery System (t:slim X2), and complementary product offerings. Its hardware and software solutions and support services help people with diabetes and their healthcare providers improve diabetes therapy management.
TypePublic
Founded2006
HQSan Diego, CA, US
Websitetandemdiabetes.com
Employee Ratings4.1
Overall CultureB

Latest Updates

Employees (est.) (Dec 2021)2,000(+34%)
Job Openings116
Revenue (FY, 2021)$702.8 M(+41%)
Share Price (Jun 2022)$60.3(-1%)
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Tandem Diabetes Care

John F. Sheridan

John F. Sheridan

President and Chief Executive Officer, Director
Michael Fechko

Michael Fechko

Vice President, Manufacturing Operations
Michael Michaud

Michael Michaud

Vice President, Research and Development
Brian Hansen

Brian Hansen

Executive Vice President and Chief Commercial Officer
Jim Leal

Jim Leal

Senior Vice President, Operations
Susan Morrison

Susan Morrison

Executive Vice President and Chief Administrative Officer
Show more

Tandem Diabetes Care Office Locations

Tandem Diabetes Care has offices in San Diego and Boise
San Diego, CA, US (HQ)
11075 Roselle St
Boise, ID, US
1500 Shoreline Dr
Show all (2)

Tandem Diabetes Care Financials and Metrics

Tandem Diabetes Care Revenue

Embed Graph
View revenue for all periods
Tandem Diabetes Care's revenue was reported to be $702.8 m in FY, 2021
USD

Revenue (Q1, 2022)

175.9m

Gross profit (Q1, 2022)

91.1m

Gross profit margin (Q1, 2022), %

51.8%

Net income (Q1, 2022)

14.7m

EBIT (Q1, 2022)

(15.3m)

Market capitalization (28-Jun-2022)

3.8b

Closing stock price (28-Jun-2022)

60.3

Cash (31-Mar-2022)

93.7m

EV

4.2b
Tandem Diabetes Care's current market capitalization is $3.8 b.
Annual
USDFY, 2019FY, 2020FY, 2021

Revenue

362.3m498.8m702.8m

Revenue growth, %

97%38%

Cost of goods sold

168.1m238.3m326.6m

Gross profit

194.2m260.5m376.2m
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

97.9m109.2m123.6m141.0m172.1m179.6m175.9m

Cost of goods sold

47.7m54.8m58.3m67.8m79.7m82.9m84.8m

Gross profit

50.3m54.4m65.3m73.3m92.5m96.7m91.1m

Gross profit Margin, %

51%50%53%52%54%54%52%
Annual
USDFY, 2019FY, 2020FY, 2021

Cash

51.2m94.6m71.2m

Accounts Receivable

46.6m82.2m110.7m

Prepaid Expenses

4.0m6.4m8.4m

Inventories

49.1m63.7m68.6m
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

74.5m222.5m129.5m120.8m98.6m112.4m93.7m

Accounts Receivable

54.0m45.0m52.1m73.7m80.2m87.5m94.1m

Prepaid Expenses

6.2m6.1m5.0m7.8m6.1m6.8m9.0m

Inventories

60.5m62.3m70.6m66.8m66.7m65.7m80.0m
Annual
USDFY, 2019FY, 2020FY, 2021

Net Income

(24.8m)(34.4m)15.6m

Depreciation and Amortization

6.1m10.5m13.8m

Inventories

(31.0m)(15.4m)(5.0m)

Accounts Payable

8.9m1.1m10.3m
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(14.9m)(42.0m)(51.4m)(5.0m)(1.0m)4.8m(14.7m)

Depreciation and Amortization

1.8m4.0m7.0m3.5m6.9m10.3m3.6m

Inventories

(11.1m)(13.2m)(22.1m)(3.1m)(3.0m)(1.9m)(12.0m)

Accounts Payable

4.3m(324.0k)3.3m10.5m12.0m10.9m13.7m
USDFY, 2019

EV/EBIT

-208.8 x

EV/CFO

83.3 x

Revenue/Employee

347.4k

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.7 x

P/E Ratio

(141.9)
Show all financial metrics

Tandem Diabetes Care Operating Metrics

FY, 2019FY, 2020FY, 2021

Patents Issued

86103117

Patents Pending

686983

Trademarks

398194

Trademarks (Foreign)

236276

Tandem Diabetes Care Acquisitions / Subsidiaries

Company NameDateDeal Size
Sugarmate, Inc.June 24, 2020
Sugarmate Inc.
Tandem Diabetes Care Canada, Inc.

Tandem Diabetes Care Revenue Breakdown

Embed Graph

Tandem Diabetes Care revenue breakdown by geographic segment: 74.7% from Domestic Sales and 25.3% from International Sales

Tandem Diabetes Care Cybersecurity Score

Cybersecurity ratingPremium dataset

D

66/100

SecurityScorecard logo

Tandem Diabetes Care Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Tandem Diabetes Care Online and Social Media Presence

Embed Graph

Tandem Diabetes Care Company Culture

  • Overall Culture

    B

    71/100

  • CEO Rating

    B

    73/100

  • Compensation

    B

    75/100

Learn more on Comparably

Tandem Diabetes Care News and Updates

Thinking about trading options or stock in Tandem Diabetes Care, Revolve Group, Callon Petroleum, Vir Biotechnology, or T-Mobile?

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNDM, RVLV, CPE, VIR, and TMUS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Should you invest in Tandem Diabetes Care, Appian Corp, Novavax, Royal Caribbean Cruises, or Boeing?

NEW YORK, Oct. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNDM, APPN, NVAX, RCL, and BA. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

lobal Artificial Pancreas Systems Market Report 2019 Top Key Players- Medtronic, Johnson and Johnson, Dexcom, Insulet, Tandem Diabetes Care and more...

A new market study, titled “Global Artificial Pancreas Systems Market Report 2019 - Market Size, Share, Price, Trend and Forecast”, has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Tandem Diabetes Care, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, June 19, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Tandem Diabetes Care, Inc. (NASDAQ: TNDM). If...

Thinking about buying stock in Apple Inc., Chesapeake Energy Corp., Cronos Group Inc., Tandem Diabetes Care, or Tesla, Inc.?

NEW YORK, Dec. 27, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CHK, CRON, TNDM, and TSLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...
Show more

Tandem Diabetes Care Frequently Asked Questions

  • When was Tandem Diabetes Care founded?

    Tandem Diabetes Care was founded in 2006.

  • Who are Tandem Diabetes Care key executives?

    Tandem Diabetes Care's key executives are John F. Sheridan, Michael Fechko and Michael Michaud.

  • How many employees does Tandem Diabetes Care have?

    Tandem Diabetes Care has 2,000 employees.

  • What is Tandem Diabetes Care revenue?

    Latest Tandem Diabetes Care annual revenue is $702.8 m.

  • What is Tandem Diabetes Care revenue per employee?

    Latest Tandem Diabetes Care revenue per employee is $351.4 k.

  • Who are Tandem Diabetes Care competitors?

    Competitors of Tandem Diabetes Care include Apria Healthcare Group, Acelity and Neurometrix.

  • Where is Tandem Diabetes Care headquarters?

    Tandem Diabetes Care headquarters is located at 11075 Roselle St, San Diego.

  • Where are Tandem Diabetes Care offices?

    Tandem Diabetes Care has offices in San Diego and Boise.

  • How many offices does Tandem Diabetes Care have?

    Tandem Diabetes Care has 2 offices.